In the extended session on Monday, the rally for Prime Medicine, Inc. (NASDAQ: PRME) stock persisted, with a noteworthy 5.61% surge after-hours, reaching $6.78. This surge further augmented the rise during regular trading hours, culminating at $6.42, marking a substantial 14.44% increase. The escalation in PRME stock value coincides with an imminent significant event.
- Executive Participation At BioConnect Investor Conference
- Innovative Prime Editing In Focus
- Addressing A Rare Genetic Disorder
Executive Participation At BioConnect Investor Conference
Prime Medicine (PRME) disclosed that its Chief Financial Officer, Allan Reine, M.D., is slated to engage in a fireside chat during the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, scheduled for Monday, May 20, 2024. Dr. Reine will delve into discussions encompassing the preclinical data showcasing the efficacy of its ex vivo Prime Editing program, PM359.
Innovative Prime Editing In Focus
Recent revelations from Prime Medicine shed light on new data concerning PM359, aimed at rectifying a prevalent disease-causing mutation associated with chronic granulomatous disease (CGD). These findings were presented at an oral session during the American Society of Cell & Gene Therapy 27th Annual Meeting in Baltimore.
Noteworthy is the clearance of PRME's investigational new drug (IND) application for PM359 by the U.S. Food and Drug Administration (FDA) for CGD treatment. This development marks a significant milestone, showcasing the transformative potential of Prime Editing technology.
Addressing A Rare Genetic Disorder
CGD, a rare hereditary ailment, poses significant health challenges, often leading to recurrent and severe infections. The disorder arises from mutations affecting the NADPH oxidase complex, impairing the body's ability to combat infections effectively. Prime Medicine's pioneering ex vivo Prime Editing program, PM359, targets the correction of the predominant mutation in CGD patients' CD34+ hematopoietic stem cells (HSCs), with promising results observed in preclinical studies.
The restoration of neutrophil function post-stem cell engraftment in animal models underscores the therapeutic potential of this innovative approach, signaling hope for patients grappling with this debilitating condition. Notably, results showed that neutrophil function could be restored in mice following stem cell engraftment and that Prime Edited cell output could be increased to a therapeutic size.
在周一的延期交易中,Prime Medicine, Inc.(纳斯达克股票代码:PRME)的股票持续上涨,盘后大幅上涨了5.61%,达到6.78美元。这种飙升进一步加剧了常规交易时段的涨幅,最终达到6.42美元,大幅上涨了14.44%。PRME股票价值的上涨恰逢即将发生的重大事件。
- 高管参加 BioConnect 投资者大会
- 聚焦创新 Prime 编辑
- 解决一种罕见的遗传性疾病
高管参加 BioConnect 投资者大会
Prime Medicine(PRME)透露,其首席财务官艾伦·雷因医学博士计划在定于2024年5月20日星期一在纳斯达克举行的H.C. Wainwright第二届年度BioConnect投资者会议上进行炉边谈话。Reine博士将深入探讨包括临床前数据的讨论,这些数据展示了其体外Prime编辑计划 PM359 的功效。
聚焦创新 Prime 编辑
Prime Medicine 最近披露的消息揭示了有关 PM359 的新数据,旨在纠正与慢性肉芽肿病 (CGD) 相关的流行致病突变。这些发现是在巴尔的摩举行的美国细胞与基因疗法学会第27届年会期间的口头会议上发表的。
值得注意的是,美国食品药品监督管理局(FDA)批准了PRME的用于CGD治疗的 PM359 研究性新药(IND)申请。这一发展标志着一个重要的里程碑,展示了Prime Editing技术的变革潜力。
解决一种罕见的遗传性疾病
CGD 是一种罕见的遗传性疾病,构成了严重的健康挑战,通常会导致反复出现的严重感染。这种疾病源于影响NADPH氧化酶复合物的突变,损害了人体有效抵抗感染的能力。Prime Medicine 开创性的体外主要编辑计划 PM359 旨在校正CGD患者CD34+造血干细胞(HSC)中的主要突变,临床前研究中观察到令人鼓舞的结果。
在动物模型中植入干细胞后,中性粒细胞功能的恢复凸显了这种创新方法的治疗潜力,为努力应对这种使人衰弱的疾病的患者带来了希望。值得注意的是,结果表明,干细胞移植后小鼠的中性粒细胞功能可以恢复,Prime Edited的细胞产量可以增加到治疗规模。